Solving the unmet need of superior vision
Sozinibercept is a novel, first-in-class VEGF-C/D ‘trap’ inhibitor designed to be used in combination with standard-of-care anti-VEGF-A therapies, with the potential to deliver superior visual outcomes.
VEGF-C/D ligands are upregulated in patients receiving anti-VEGF-A therapies causing the formation of leaky blood vessels which may lead to vision loss and drive disease progression.
Sozinibercept traps VEGF-C and VEGF-D protein ligands to inhibit VEGF-C/D mediated angiogenesis through VEGFR-2 and VEGFR-3 receptors.
By preventing blood vessel growth and vascular leakage in the retina, sozinibercept has the potential to deliver superior visual outcomes when used in combination with standard-of-care anti-VEGF-A therapies.
How Sozinibercept Works In The Eye
Through our bold innovation, we seek to transform the lives of people living with blinding diseases including wet AMD.
Our novel, first-in-class VEGF-C/D ‘trap’ inhibitor has the potential to deliver superior visual outcomes in combination with standard-of-care.
Opthea’s lead product candidate, sozinibercept is the only drug in late-stage clinical development for wet AMD with the potential to be the first product in 20 years to deliver superior visual gains for patients suffering from this debilitating disease.
Explore publications relevant to sozinibercept, our clinical trials and the science behind our innovations.